Epizyme, Inc. (EPZM)
| Market Cap | 554.20M |
| Revenue (ttm) | 32.58M |
| Net Income (ttm) | -256.94M |
| Shares Out | 102.05M |
| EPS (ttm) | -2.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 478,361 |
| Open | 5.46 |
| Previous Close | 5.47 |
| Day's Range | 5.30 - 5.50 |
| 52-Week Range | 4.72 - 14.30 |
| Beta | 1.17 |
| Analysts | Buy |
| Price Target | 11.14 (+109.0%) |
| Est. Earnings Date | Nov 4, 2021 |
About EPZM
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops Tazemetostat in combination with rituximab in patients with follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with...
Financial Performance
In 2020, Epizyme's revenue was $15.76 million, a decrease of -33.77% compared to the previous year's $23.80 million. Losses were -$231.69 million, 36.1% more than in 2019.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for Epizyme stock is "Buy." The 12-month stock price forecast is 11.14, which is an increase of 109.01% from the latest price.
News
Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that...
Why Is Epizyme (EPZM) Up 3.8% Since Last Earnings Report?
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the C...
Epizyme's (EPZM) Q2 Earnings Miss, Revenues Beat Estimates
Epizyme (EPZM) reports wider-than-expected loss for the second quarter of 2021 despite its revenues beating estimates. As a result, stock price declines.
Why Epizyme Is Getting Crushed Today
It's uncomfortable when a company delivers an earnings miss and announces a CEO's departure on the same day.
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates
Epizyme (EPZM) delivered earnings and revenue surprises of -5.00% and 48.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Epizyme Q2 Earnings
Shares of Epizyme (NASDAQ:EPZM) moved higher by 13.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 8.62% year over year to ($0.63), which m...
Epizyme Announces CEO Succession
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies today announced its C...
Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today reported its second ...
Epizyme Stock Gains On Potential $310M Pact With HUTCHMED For Cancer-Focused Tazverik In Greater China
Epizyme Inc (NASDAQ: EPZM) and HUTCHMED (China) Limited (NASDAQ: HCM) have collaborated to research, develop, manufacture, and commercialize Tazverik (tazemetostat) in Greater China, including mainland ...
Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greate...
CAMBRIDGE, Mass. & HONG KONG & SHANGHAI & FLORHAM PARK, N.J.--(BUSINESS WIRE)--Epizyme, Inc. (“Epizyme”) (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and del...
Epizyme Announces Date of Second Quarter 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that mana...
Analysts Estimate Epizyme (EPZM) to Report a Decline in Earnings: What to Look Out for
Epizyme (EPZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Epizyme Stock Is Falling This Week
The cancer drug developer's CFO will soon exit the company.
Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today launched the EZH2Now...
Epizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models
Epizyme Inc (NASDAQ: EPZM) has reported positive data from mouse studies for potential first-in-class therapy, EPZ-719, that targets the enzyme SETD2. The chromosomal abnormality is responsible for abou...
Epizyme to Participate in Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Robe...
Epizyme Announces Preclinical and Clinical Data to be Presented in Oral and Poster Sessions at Upcoming Medical Confe...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that...
Epizyme's (EPZM) Q1 Earnings Miss, Revenues Beat Estimates
Epizyme (EPZM) reports wider-than-expected loss in the first quarter of 2021 despite its revenues beating estimates.
Epizyme (EPZM) Reports Q1 Loss, Tops Revenue Estimates
Epizyme (EPZM) delivered earnings and revenue surprises of -23.21% and 7.71%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Epizyme Provides Business Update and Reports First Quarter 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided business an...
Epizyme Announces Date of First Quarter 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that mana...
5 Small-Cap Biotech Stocks Trading Under $10 With Massive Upside Potential
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Epizyme (EPZM) Down 22.9% Since Last Earnings Report: Can It Rebound?
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?